Psyched Wellness - CEO and Director, Jeff Stevens.
CEO and Director, Jeff Stevens.
Source: Twitter.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Psyched Wellness (PSYC) plans to launch its Amanita Muscaria (AME-1) products in the U.S. in Q2 2022
  • The company’s products will undergo regulatory analysis in both Canada and the U.S.
  • These processes will allow for sales across conventional food, dietary supplement and natural health product categories
  • Psyched Wellness is a health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods
  • Psyched Wellness (PSYC) is up by 9.09 per cent and is currently trading at $0.12 per share

Psyched Wellness (PSYC) plans to launch its Amanita Muscaria products in the U.S. in Q2 2022.

The company is having a self-generally recognized as safe dossier reviewed by an external panel of experts. The process permits substances to be exempted from premarket review by the F.D.A.

It also plans to submit to Health Canada for a natural health product number.

These regulatory processes will allow Psyched to sell in multiple categories including U.S. conventional foods, U.S. dietary supplements and Canadian natural health products.

The company is working closely with KGK Science to apply for all requisite approvals.

“This is an important and logical step forward as we pursue our strategy to create premium Amanita Muscaria mushroom-derived products and become a leading North American brand in the emerging functional food category,” said Jeff Stevens, CEO of Psyched Wellness.

Psyched Wellness is a health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods.

Psyched Wellness (PSYC) is up by 9.09 per cent and is currently trading at $0.12 per share as of 11:07 am EST.

More From The Market Herald

" Optimi Health (CSE:OPTI) acquires catalog of psychedelic and functional mushroom genetics

Optimi Health (OPTI) has acquired a catalog of psilocybin and functional mushroom strains.

" Nirvana Life Sciences Inc (CSE:NIRV) signs LOI with Innovate Phytotechnologies Inc

Nirvana Life Sciences (NIRV) has  signed a letter of intent with Innovate Phytotechnologies Inc. (INVP)
Clearmind Medicine - CEO, Adi Zuloff Shani.

" Clearmind Medicine (CSE:CMND) announces upcoming pre-IND meeting with the FDA

Clearmind (CMND) will participate in a pre-IND meeting with the FDA on May 18, 2022.
Red Light Holland - Advisor, Akwasi Owusu Bempah.

" Red Light Holland (CSE:TRIP) adds Akwasi Owusu-Bempah to Advisory Board

Red Light Holland (TRIP) has hired drug law expert Akwasi Owusu-Bempah as its newest advisor.